Literature DB >> 33769791

Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.

Songzhe He1,2,3, Fushun Wang4,5, Ken Kin Lam Yung6, Shiqing Zhang6, Shaogang Qu1,2,3.   

Abstract

α-Synuclein (α-syn), a small highly conserved presynaptic protein containing 140 amino acids, is thought to be the main pathological hallmark in related neurodegenerative disorders. Although the normal function of α-syn is closely involved in the regulation of vesicular neurotransmission in these diseases, the underlying mechanisms of post-translational modifications (PTMs) of α-syn in the pathogenesis of Parkinson's disease (PD) have not been fully characterized. The pathological accumulation of misfolded α-syn has a critical role in PD pathogenesis. Recent studies of factors contributing to α-syn-associated aggregation and misfolding have expanded our understanding of the PD disease process. In this Review, we summarize the structure and physiological function of α-syn, and we further highlight the major PTMs (namely phosphorylation, ubiquitination, nitration, acetylation, truncation, SUMOylation, and O-GlcNAcylation) of α-syn and the effects of these modifications on α-syn aggregation, which may elucidate mechanisms for PD pathogenesis and lay a theoretical foundation for clinical treatment of PD.

Entities:  

Keywords:  Parkinson’s disease; neurodegenerative diseases; post-translational modifications; protein aggregation; protein misfolding; α-Synuclein

Mesh:

Substances:

Year:  2021        PMID: 33769791     DOI: 10.1021/acschemneuro.1c00028

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  5 in total

Review 1.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

2.  Benzo[d]thiazol-5-yl Compounds as O-GlcNAcase Inhibitors for Treating Alzheimer's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-05-18       Impact factor: 4.632

Review 3.  Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.

Authors:  Milton H Werner; C Warren Olanow
Journal:  Mov Disord       Date:  2021-11-23       Impact factor: 9.698

4.  Glycation modulates alpha-synuclein fibrillization kinetics: A sweet spot for inhibition.

Authors:  Azad Farzadfard; Annekatrin König; Steen Vang Petersen; Janni Nielsen; Eftychia Vasili; Antonio Dominguez-Meijide; Alexander K Buell; Tiago Fleming Outeiro; Daniel E Otzen
Journal:  J Biol Chem       Date:  2022-03-18       Impact factor: 5.486

Review 5.  Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.